GlassScriptPhysician profile
Dianne Kyle
NPI 1770934655
$8,858.26
in general payments reported to CMS, 2019-2025
28 companies · $2,525 in 2025
The $2,525 reported for 2025 was more than what 97% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $18.38 · 2022: $1,377 · 2023: $1,638 · 2024: $3,300 · 2025: $2,525.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,452 · Education: $11.29.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,451.59 |
| Education | $11.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,292.56 | 2022-2025 | |
| Novo Nordisk INC | $1,386.89 | 2022-2025 | Wegovy, Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $1,226.89 | 2022-2025 | Airsupra, Breztri, Farxiga |
| Amgen INC. | $1,151.75 | 2024-2025 | Evenity, Repatha, Otezla |
| Janssen Pharmaceuticals, INC | $526.08 | 2022-2024 | Spravato, Xarelto |
| Ibsa Pharma INC. | $250.00 | 2024 | Tirosint |
| Exact Sciences Corporation | $243.22 | 2023-2025 | Cologuard Collection Kit |
| Lilly USA, LLC | $177.09 | 2022-2025 | Mounjaro, Zepbound |
| Bayer Healthcare Pharmaceuticals INC. | $160.59 | 2022-2023 | |
| Glaxosmithkline, LLC. | $141.85 | 2023-2024 | Shingrix, Arexvy |
| Corcept Therapeutics | $136.85 | 2025 | Korlym |
| Sobi, INC | $125.00 | 2023 | |
| Exeltis, USA INC. | $125.00 | 2025 | |
| Pharming Healthcare, INC. | $124.99 | 2024 | Ruconest |
| Astellas Pharma US INC | $114.30 | 2025 | Veozah |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Scynexis, INC. | $113.88 | 2022 | |
| Alexion Pharmaceuticals, INC. | $102.72 | 2023 | Ultomiris |
| Alkermes, INC. | $100.00 | 2022 | |
| Xeris Pharmaceuticals, INC. | $94.88 | 2022 | |
| Pfizer INC. | $60.65 | 2024-2025 | |
| Sanofi-Aventis U.S. LLC | $41.18 | 2024-2025 | |
| Abbott Laboratories | $37.45 | 2023-2024 | Freestyle Libre 3 |
| Boehringer Ingelheim Pharmaceuticals, INC. | $30.27 | 2022-2023 | Jardiance |
| Antares Pharma, INC. | $23.49 | 2022 | |
| Medtronic, INC. | $20.66 | 2025 | Inceptiv |
| Genentech USA, INC. | $18.38 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $18.15 | 2022 | |
| Idorsia Pharmaceuticals US INC | $13.49 | 2023 | Quviviq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dianne Kyle listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.